Light Meets Precision With A Click: SCALPEL Officially Kicks Off in Oslo

On March 20–21, 2025, the six SCALPEL project partners from across Europe gathered in Oslo, Norway, to mark the official launch of a pioneering initiative that is set to redefine the future of cancer treatment.

A Bold Vision, United Across Disciplines

SCALPEL is more than a research project, it is a bold, multidisciplinary movement bringing together expertise from photomedicine, immunotherapy, molecular biology and biomedical engineering. By combining light-based therapy with cutting-edge immunological techniques, SCALPEL aims to introduce a novel therapeutic approach: precision-targeted antibodies that “click” into action upon light activation. This allows for highly selective cancer cell elimination while preserving surrounding healthy tissue.

The Kick-Off Meeting set the tone for the years ahead. It was a high-energy, collaborative exchange where each partner introduced their team, shared their scientific vision and outlined their roles and contributions. Together, participants explored the full potential of each work package, tackled challenges with creative solutions and coordinated the next concrete steps to bring this transformative therapy closer to reality.

Why SCALPEL Matters

• Precision treatment with fewer side effects
• Targeted, light-activated therapy that works only where and when needed
• An innovative path toward drug-free remission and long-term cancer immunity
• A multidisciplinary European collaboration to advance next-generation cancer care

SCALPEL is driven by a shared mission: to push the boundaries of precision oncology and open new therapeutic frontiers for those living with cancer. It represents a new chapter in cancer treatment, one powered by light, shaped by science and made possible through deep collaboration.

Follow the Journey

This is just the beginning. As SCALPEL moves forward, we invite you to join us in shaping a new future for cancer therapy. Follow our journey as we explore the power of light and unlock the potential of immunotherapy.